<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01746589</url>
  </required_header>
  <id_info>
    <org_study_id>FS200SVR-10-2011</org_study_id>
    <nct_id>NCT01746589</nct_id>
  </id_info>
  <brief_title>Visual Outcomes and Contrast Sensitivity After Myopic LASIK</brief_title>
  <official_title>Evaluation Of Visual Outcomes and Contrast Sensitivity After Myopic Wavefront-Optimized Lasik Using the 200 KHZ WAVELIGHT® FS200 Femtosecond Laser and the WAVELIGHT® ALLEGRETTO WAVE® EYE-Q Laser</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Daniel S. Durrie, MD</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Alcon Research</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Durrie Vision</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Evaluate visual outcomes and contrast sensitivity for subjects undergoing bilateral myopic&#xD;
      LASIK procedure using the 200 kHz WaveLight® FS200 Femtosecond Laser and the WaveLight®&#xD;
      Allegretto Wave® Eye-Q Laser. The use of advanced technology may decrease the loss of&#xD;
      contrast sensitivity and improvement of postoperative visual acuity results.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>November 2011</start_date>
  <completion_date type="Actual">January 2012</completion_date>
  <primary_completion_date type="Actual">January 2012</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in Uncorrected Visual Acuity over time postoperatively</measure>
    <time_frame>Postoperatively immediate (1-3 minutes), 30 minutes, 1 hour, 2 hours, 4 hours, 1 day, and 1 month</time_frame>
    <description>Change in uncorrected visual acuity from baseline, postoperatively, immediately(1-3 minutes) after surgery, 30 minutes, 1 hour, 2 hours, 4 hours, 1 day, and 1 month.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change in contrast sensitivity postoperatively as compared to baseline</measure>
    <time_frame>Postoperatively at immediately (1-3 minutes) after surgery, 30 minutes, 1 hour, 2 hours, 4 hours, 1 day and 1 month</time_frame>
    <description>Contrast sensitivity (ability to distinguish between shades of gray) will be measured postoperatively immediately (1-3 minutes) after surgery, 30 minutes,1 hour, 2 hours, 4 hours, 1 day, and 1 month.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">22</enrollment>
  <condition>Myopia</condition>
  <arm_group>
    <arm_group_label>myopic LASIK procedure</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>All subjects will receive bilateral myopic LASIK procedure using the 200 kHz WaveLight® FS200 Femtosecond Laser and the WaveLight® Allegretto Wave® Eye-Q Laser</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>bilateral myopic LASIK</intervention_name>
    <description>200 kHz WaveLight® FS200 Femtosecond Laser and the WaveLight® Allegretto Wave® Eye-Q Laser</description>
    <arm_group_label>myopic LASIK procedure</arm_group_label>
    <other_name>WaveLight® Femtosecond Laser and WaveLight® Allegretto®</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        INCLUSION CRITERIA&#xD;
&#xD;
          -  Male or female in good general health, 18 years of age or older at the time of the&#xD;
             pre-operative examination&#xD;
&#xD;
          -  Patient must be able to read, comprehend and willing to give HIPPA and informed&#xD;
             consent&#xD;
&#xD;
          -  Patient is planning to undergo a bilateral LASIK procedure&#xD;
&#xD;
          -  Both eyes must have a manifest refractive error from -1.00 D to -7.00 spherical&#xD;
             equivalent with less than or equal to 3.00D of refractive astigmatism as expressed in&#xD;
             spectacle minus cylinder form&#xD;
&#xD;
          -  Both eyes must have a BSCVA of 20/20 or better&#xD;
&#xD;
          -  Both eyes must demonstrate refractive stability confirmed by clinical records,&#xD;
             previous glasses, or investigator's discretion.&#xD;
&#xD;
          -  Patient must be willing to comply with study dosing and complete the entire course of&#xD;
             the study.&#xD;
&#xD;
        EXCLUSION CRITERIA&#xD;
&#xD;
          -  A patient with evidence of keratoconus, corneal irregularity, or abnormal&#xD;
             videokeratography in either eye&#xD;
&#xD;
          -  A patient seeking monovision&#xD;
&#xD;
          -  A patient with a known hypersensitivity to any of the components of the procedural or&#xD;
             post-LASIK medications&#xD;
&#xD;
          -  A patient requiring the use of any ocular drop(s) and/or medication(s) in either eye&#xD;
             during the study period with the exception of ocular drops and/or medications provided&#xD;
             by the investigator&#xD;
&#xD;
          -  A patient having any surgical procedure within a week preceding the scheduled LASIK&#xD;
             surgery&#xD;
&#xD;
          -  A patient with any UNCONTROLLED systemic disease (i.e., a potential patient in whom&#xD;
             therapy for a systemic disease is not yet stabilized )&#xD;
&#xD;
          -  A patient with a history of prior intraocular or corneal surgery (including cataract&#xD;
             extraction), active clinically significant ophthalmic disease or abnormality&#xD;
             (including, but not limited to, blepharitis, recurrent corneal erosion, dry eye&#xD;
             syndrome, neovascularization &gt; 1mm from limbus), clinically significant lens opacity,&#xD;
             clinical evidence of trauma (including scarring) inside the visual axis, or evidence&#xD;
             of glaucoma or propensity for narrow angle glaucoma in either eye&#xD;
&#xD;
          -  A patient with a significant history or current evidence of a medical, psychological&#xD;
             or other disorder that, in the investigator's opinion, may increase the risk&#xD;
             associated with study participation or may interfere with the interpretation of study&#xD;
             results&#xD;
&#xD;
          -  A patient with a history of any of the following medical conditions, or any other&#xD;
             condition that could affect wound healing: uncontrolled diabetes, collagen vascular&#xD;
             disease, autoimmune disease, immunodeficiency diseases, ocular herpes zoster or&#xD;
             simplex, endocrine disorders (including, but not limited to unstable thyroid disorders&#xD;
             and diabetes), lupus, and rheumatoid arthritis&#xD;
&#xD;
          -  Current participation or participation within 30 days prior to the start of this study&#xD;
             in a drug or other investigational research study.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Durrie Vision</name>
      <address>
        <city>Overland Park</city>
        <state>Kansas</state>
        <zip>66211</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>January 2013</verification_date>
  <study_first_submitted>December 7, 2012</study_first_submitted>
  <study_first_submitted_qc>December 7, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 11, 2012</study_first_posted>
  <last_update_submitted>January 25, 2013</last_update_submitted>
  <last_update_submitted_qc>January 25, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">January 28, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Durrie Vision</investigator_affiliation>
    <investigator_full_name>Daniel S. Durrie, MD</investigator_full_name>
    <investigator_title>President</investigator_title>
  </responsible_party>
  <keyword>LASIK</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Myopia</mesh_term>
    <mesh_term>Hypersensitivity</mesh_term>
  </condition_browse>
  <pending_results>
    <submitted>February 18, 2015</submitted>
    <returned>March 3, 2015</returned>
  </pending_results>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

